Skip to main content
Erschienen in: Diabetologia 8/2011

01.08.2011 | Article

Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets

verfasst von: J. M. Luther, P. Luo, M. T. Kreger, M. Brissova, C. Dai, T. T. Whitfield, H. S. Kim, D. H. Wasserman, A. C. Powers, N. J. Brown

Erschienen in: Diabetologia | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Aldosterone concentrations increase in obesity and predict the onset of diabetes. We investigated the effects of aldosterone on glucose homeostasis and insulin secretion in vivo and in vitro.

Methods

We assessed insulin sensitivity and insulin secretion in aldosterone synthase-deficient (As [also known as Cyp11b2]−/−) and wild-type mice using euglycaemic–hyperinsulinaemic and hyperglycaemic clamps, respectively. We also conducted studies during high sodium intake to normalise renin activity and potassium concentration in As −/− mice. We subsequently assessed the effect of aldosterone on insulin secretion in vitro in the presence or absence of mineralocorticoid receptor antagonists in isolated C57BL/6J islets and in the MIN6 beta cell line.

Results

Fasting glucose concentrations were reduced in As −/− mice compared with wild-type. During hyperglycaemic clamps, insulin and C-peptide concentrations increased to a greater extent in As −/− than in wild-type mice. This was not attributable to differences in potassium or angiotensin II, as glucose-stimulated insulin secretion was enhanced in As −/− mice even during high sodium intake. There was no difference in insulin sensitivity between As −/− and wild-type mice in euglycaemic–hyperinsulinaemic clamp studies. In islet and MIN6 beta cell studies, aldosterone inhibited glucose- and isobutylmethylxanthine-stimulated insulin secretion, an effect that was not blocked by mineralocorticoid receptor antagonism, but was prevented by the superoxide dismutase mimetic tempol.

Conclusions/interpretation

We demonstrated that aldosterone deficiency or excess modulates insulin secretion in vivo and in vitro via reactive oxygen species and in a manner that is independent of mineralocorticoid receptors. These findings provide insight into the mechanism of glucose intolerance in conditions of relative aldosterone excess.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rocha R, Stier CT Jr, Kifor I et al (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871–3878PubMedCrossRef Rocha R, Stier CT Jr, Kifor I et al (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871–3878PubMedCrossRef
2.
Zurück zum Zitat Goodfriend TL, Egan BM, Kelley DE (1999) Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 60:401–405PubMedCrossRef Goodfriend TL, Egan BM, Kelley DE (1999) Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 60:401–405PubMedCrossRef
3.
Zurück zum Zitat Bochud M, Nussberger J, Bovet P et al (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48:239–245PubMedCrossRef Bochud M, Nussberger J, Bovet P et al (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48:239–245PubMedCrossRef
4.
Zurück zum Zitat Ingelsson E, Pencina MJ, Tofler GH et al (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116:984–992PubMedCrossRef Ingelsson E, Pencina MJ, Tofler GH et al (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116:984–992PubMedCrossRef
5.
Zurück zum Zitat Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M (1981) The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304:930–933PubMedCrossRef Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M (1981) The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304:930–933PubMedCrossRef
6.
Zurück zum Zitat Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K (2004) Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43:358–363PubMedCrossRef Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K (2004) Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43:358–363PubMedCrossRef
7.
Zurück zum Zitat Conn JW (1965) Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 273:1135–1143PubMedCrossRef Conn JW (1965) Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 273:1135–1143PubMedCrossRef
8.
Zurück zum Zitat Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA (2007) Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30:2349–2354PubMedCrossRef Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA (2007) Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30:2349–2354PubMedCrossRef
9.
Zurück zum Zitat Catena C, Lapenna R, Baroselli S et al (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91:3457–3463PubMedCrossRef Catena C, Lapenna R, Baroselli S et al (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91:3457–3463PubMedCrossRef
10.
Zurück zum Zitat Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846PubMedCrossRef Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846PubMedCrossRef
11.
Zurück zum Zitat Mosso LM, Carvajal CA, Maiz A et al (2007) A possible association between primary aldosteronism and a lower β-cell function. J Hypertens 25:2125–2130PubMedCrossRef Mosso LM, Carvajal CA, Maiz A et al (2007) A possible association between primary aldosteronism and a lower β-cell function. J Hypertens 25:2125–2130PubMedCrossRef
12.
Zurück zum Zitat Bosch J, Yusuf S, Gerstein HC et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562PubMedCrossRef Bosch J, Yusuf S, Gerstein HC et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562PubMedCrossRef
13.
Zurück zum Zitat McMurray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490PubMedCrossRef McMurray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490PubMedCrossRef
14.
Zurück zum Zitat Makhanova N, Lee G, Takahashi N et al (2006) Kidney function in mice lacking aldosterone. Am J Physiol Renal Physiol 290:F61–F69PubMedCrossRef Makhanova N, Lee G, Takahashi N et al (2006) Kidney function in mice lacking aldosterone. Am J Physiol Renal Physiol 290:F61–F69PubMedCrossRef
15.
Zurück zum Zitat Luther JM, Wang Z, Ma J, Makhanova N, Kim HS, Brown NJ (2009) Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Endocrinology 150:2229–2236PubMedCrossRef Luther JM, Wang Z, Ma J, Makhanova N, Kim HS, Brown NJ (2009) Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Endocrinology 150:2229–2236PubMedCrossRef
16.
Zurück zum Zitat Lee G, Makhanova N, Caron K et al (2005) Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice. Endocrinology 146:2650–2656PubMedCrossRef Lee G, Makhanova N, Caron K et al (2005) Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice. Endocrinology 146:2650–2656PubMedCrossRef
17.
Zurück zum Zitat Ayala JE, Bracy DP, McGuinness OP, Wasserman DH (2006) Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390–397PubMedCrossRef Ayala JE, Bracy DP, McGuinness OP, Wasserman DH (2006) Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390–397PubMedCrossRef
18.
Zurück zum Zitat Fueger PT, Hess HS, Bracy DP et al (2004) Regulation of insulin-stimulated muscle glucose uptake in the conscious mouse: role of glucose transport is dependent on glucose phosphorylation capacity. Endocrinology 145:4912–4916PubMedCrossRef Fueger PT, Hess HS, Bracy DP et al (2004) Regulation of insulin-stimulated muscle glucose uptake in the conscious mouse: role of glucose transport is dependent on glucose phosphorylation capacity. Endocrinology 145:4912–4916PubMedCrossRef
19.
Zurück zum Zitat Berglund ED, Li CY, Poffenberger G et al (2008) Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 57:1790–1799PubMedCrossRef Berglund ED, Li CY, Poffenberger G et al (2008) Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 57:1790–1799PubMedCrossRef
20.
Zurück zum Zitat Brissova M, Shiota M, Nicholson WE et al (2002) Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 277:11225–11232PubMedCrossRef Brissova M, Shiota M, Nicholson WE et al (2002) Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 277:11225–11232PubMedCrossRef
21.
Zurück zum Zitat Miyazaki J, Araki K, Yamato E et al (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127:126–132PubMedCrossRef Miyazaki J, Araki K, Yamato E et al (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127:126–132PubMedCrossRef
22.
23.
Zurück zum Zitat Garthwaite SM, McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27–31PubMedCrossRef Garthwaite SM, McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27–31PubMedCrossRef
24.
Zurück zum Zitat Gomez-Sanchez CE, de Rodriguez AF, Romero DG et al (2006) Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 147:1343–1348PubMedCrossRef Gomez-Sanchez CE, de Rodriguez AF, Romero DG et al (2006) Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 147:1343–1348PubMedCrossRef
25.
Zurück zum Zitat Uehara S, Tsuchida M, Kanno T, Sasaki M, Nishikibe M, Fukamizu A (2003) Late-onset obesity in mice transgenic for the human renin gene. Int J Mol Med 11:723–727PubMed Uehara S, Tsuchida M, Kanno T, Sasaki M, Nishikibe M, Fukamizu A (2003) Late-onset obesity in mice transgenic for the human renin gene. Int J Mol Med 11:723–727PubMed
26.
Zurück zum Zitat Gratze P, Boschmann M, Dechend R et al (2009) Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity? Hypertension 53:516–523PubMedCrossRef Gratze P, Boschmann M, Dechend R et al (2009) Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity? Hypertension 53:516–523PubMedCrossRef
27.
Zurück zum Zitat Hitomi H, Kiyomoto H, Nishiyama A et al (2007) Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50:750–755PubMedCrossRef Hitomi H, Kiyomoto H, Nishiyama A et al (2007) Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50:750–755PubMedCrossRef
28.
Zurück zum Zitat Lastra G, Whaley-Connell A, Manrique C et al (2008) Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 295:E110–E116PubMedCrossRef Lastra G, Whaley-Connell A, Manrique C et al (2008) Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 295:E110–E116PubMedCrossRef
29.
Zurück zum Zitat Carlsson PO, Berne C, Jansson L (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41:127–133PubMedCrossRef Carlsson PO, Berne C, Jansson L (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41:127–133PubMedCrossRef
30.
Zurück zum Zitat Leung PS, Chan WP, Wong TP, Sernia C (1999) Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 160:13–19PubMedCrossRef Leung PS, Chan WP, Wong TP, Sernia C (1999) Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 160:13–19PubMedCrossRef
31.
Zurück zum Zitat Scheen AJ (2004) Prevention of type 2 diabetes mellitus through inhibition of the renin–angiotensin system. Drugs 64:2537–2565PubMedCrossRef Scheen AJ (2004) Prevention of type 2 diabetes mellitus through inhibition of the renin–angiotensin system. Drugs 64:2537–2565PubMedCrossRef
32.
Zurück zum Zitat Sindelka G, Widimsky J, Haas T, Prazny M, Hilgertova J, Skrha J (2000) Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 108:21–25PubMed Sindelka G, Widimsky J, Haas T, Prazny M, Hilgertova J, Skrha J (2000) Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 108:21–25PubMed
33.
Zurück zum Zitat Voiculescu A, Hollenbeck M, Kutkuhn B, Grabensee B, Plum J (2003) Successful treatment of renovascular hypertension has no effect on insulin sensitivity. Eur J Clin Investig 33:848–854CrossRef Voiculescu A, Hollenbeck M, Kutkuhn B, Grabensee B, Plum J (2003) Successful treatment of renovascular hypertension has no effect on insulin sensitivity. Eur J Clin Investig 33:848–854CrossRef
34.
Zurück zum Zitat Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638–1644PubMedCrossRef Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638–1644PubMedCrossRef
35.
Zurück zum Zitat Pierluissi J, Navas FO, Ashcroft SJ (1986) Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 29:119–121PubMedCrossRef Pierluissi J, Navas FO, Ashcroft SJ (1986) Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 29:119–121PubMedCrossRef
36.
Zurück zum Zitat Chuang JC, Cha JY, Garmey JC, Mirmira RG, Repa JJ (2008) Research resource: nuclear hormone receptor expression in the endocrine pancreas. Mol Endocrinol 22:2353–2363PubMedCrossRef Chuang JC, Cha JY, Garmey JC, Mirmira RG, Repa JJ (2008) Research resource: nuclear hormone receptor expression in the endocrine pancreas. Mol Endocrinol 22:2353–2363PubMedCrossRef
37.
Zurück zum Zitat Lemarie CA, Simeone SM, Nikonova A et al (2009) Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 105:852–859PubMedCrossRef Lemarie CA, Simeone SM, Nikonova A et al (2009) Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 105:852–859PubMedCrossRef
38.
Zurück zum Zitat Boldyreff B, Wehling M (2003) Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells. Nephrol Dial Transplant 18:1693–1695PubMedCrossRef Boldyreff B, Wehling M (2003) Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells. Nephrol Dial Transplant 18:1693–1695PubMedCrossRef
39.
Zurück zum Zitat Hirasawa G, Sasano H, Ki T et al (1997) Colocalization of 11β-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. J Clin Endocrinol Metab 82:3859–3863PubMedCrossRef Hirasawa G, Sasano H, Ki T et al (1997) Colocalization of 11β-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. J Clin Endocrinol Metab 82:3859–3863PubMedCrossRef
40.
Zurück zum Zitat Losel R, Schultz A, Boldyreff B, Wehling M (2004) Rapid effects of aldosterone on vascular cells: clinical implications. Steroids 69:575–578PubMedCrossRef Losel R, Schultz A, Boldyreff B, Wehling M (2004) Rapid effects of aldosterone on vascular cells: clinical implications. Steroids 69:575–578PubMedCrossRef
41.
Zurück zum Zitat Gekle M, Grossmann C (2009) Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 458:231–246PubMedCrossRef Gekle M, Grossmann C (2009) Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 458:231–246PubMedCrossRef
42.
Zurück zum Zitat Briet M, Schiffrin EL (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6:261–273PubMedCrossRef Briet M, Schiffrin EL (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6:261–273PubMedCrossRef
43.
Zurück zum Zitat Drews G, Krippeit-Drews P, Dufer M (2010) Oxidative stress and beta-cell dysfunction. Pflugers Arch 460:703–718PubMedCrossRef Drews G, Krippeit-Drews P, Dufer M (2010) Oxidative stress and beta-cell dysfunction. Pflugers Arch 460:703–718PubMedCrossRef
44.
Zurück zum Zitat Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC (2007) Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 21:2185–2194PubMedCrossRef Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC (2007) Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 21:2185–2194PubMedCrossRef
45.
Zurück zum Zitat Shimamoto K, Shiiki M, Ise T et al (1994) Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 8:755–759PubMed Shimamoto K, Shiiki M, Ise T et al (1994) Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 8:755–759PubMed
46.
Zurück zum Zitat Weinberger MH, White WB, Ruilope LM et al (2005) Effects of eplerenone vs losartan in patients with low-renin hypertension. Am Heart J 150:426–433PubMedCrossRef Weinberger MH, White WB, Ruilope LM et al (2005) Effects of eplerenone vs losartan in patients with low-renin hypertension. Am Heart J 150:426–433PubMedCrossRef
47.
Zurück zum Zitat Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD (2008) Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 51:762–768PubMedCrossRef Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD (2008) Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 51:762–768PubMedCrossRef
48.
Zurück zum Zitat Arase Y, Suzuki F, Suzuki Y et al (2009) Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol 81:1584–1590PubMedCrossRef Arase Y, Suzuki F, Suzuki Y et al (2009) Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol 81:1584–1590PubMedCrossRef
49.
Zurück zum Zitat Strauch B, Widimsky J, Sindelka G, Skrha J (2003) Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 52:503–506PubMed Strauch B, Widimsky J, Sindelka G, Skrha J (2003) Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 52:503–506PubMed
50.
Zurück zum Zitat Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF (2010) Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56:831–838PubMedCrossRef Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF (2010) Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56:831–838PubMedCrossRef
Metadaten
Titel
Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets
verfasst von
J. M. Luther
P. Luo
M. T. Kreger
M. Brissova
C. Dai
T. T. Whitfield
H. S. Kim
D. H. Wasserman
A. C. Powers
N. J. Brown
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 8/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2158-9

Weitere Artikel der Ausgabe 8/2011

Diabetologia 8/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.